TRITON Study Targets Lung Cancers That Resist Standard Immunotherapy

Not all lung cancers respond equally well to today's standard immunotherapy combinations. Tumors carrying STK11 and/or KEAP1 mutations, often alongside KRAS mutations, have consistently shown weaker responses to typical checkpoint-inhibitor-based regimens — prompting a specific wave of research aimed at this genetically defined, immunotherapy-resistant subgroup.

Interim results from the phase 2b TRITON study suggest that adding tremelimumab, a second immune-checkpoint-targeting antibody, to the standard durvalumab-plus-chemotherapy backbone may improve outcomes specifically in nonsquamous metastatic NSCLC patients whose tumors carry STK11, KEAP1, and/or KRAS mutations.

Researchers involved in the analysis told reporters that dual checkpoint inhibition might help overcome immunotherapy resistance tied to these particular genotypes, though they cautioned that confirmation with more mature survival data is still needed before the approach could change standard practice.

Biomarker-guided trial design — testing a treatment specifically in the genetic subgroup it is most likely to help, rather than in all comers — has become a defining feature of lung cancer research over the past decade. Our article library covers how biomarker testing at diagnosis increasingly shapes treatment planning.